CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
Evacetrapibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01836185
NCT01836185Phase 1Completed
CompareCT.gov

Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment

Eli Lilly and Company·interventional·Posted Apr 19, 2013·Updated Oct 12, 2018

In Brief

A Phase 1 clinical trial evaluating Evacetrapib for Hepatic Insufficiency. Completed, enrolled 32 participants across 2 sites.

Detailed Summary

The purpose of this study is to measure how much of the drug gets into the bloodstream and how long it takes the body to remove it when given to participants with hepatic (liver) impairment compared to participants with normal hepatic function. Information about any side effects that may occur will also be collected. This study will last approximately 28 days, not including screening.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Insufficiency
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 19, 2013
Enrollment StartApr 1, 2013
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 13.2 years ago

Interventions

Evacetrapibdrug